arrow
A

Andrea Duminuco

University of Catania
H指数:14
被引数:735

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real-world evidence

鲁索利替尼治疗失败后的骨髓纤维化患者:一种系统评价和合并分析,包括临床试验和真实世界证据中的III期疗效和综合安全性

2026-09-060
OAAI
Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience

阿卡巴鲁替尼在慢性淋巴细胞白血病中的真实世界有效性与安全性:多中心经验

2026-07-020
OAAI
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study

美洛替尼在鲁索利替尼治疗失败后的临床获益及疗效预测因素:一项合作性真实世界研究

Cancer
IF5.1
2026-05-120
OAAI
Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes

伴有慢性粒细胞白血病的骨髓增殖性肿瘤与TKI耐药和不良预后相关

Leukemia
IF13.4
2026-03-270
OAAI
Plasma metabolomics and ctDNA analysis in newly diagnosed diffuse large B-cell lymphoma: an exploratory study

新诊断弥漫性大B细胞淋巴瘤的血浆代谢组学和ctDNA分析:一项探索性研究

2026-01-010
OAAI
Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia

更正:CPX-351在60岁以下继发急性髓系白血病患者中的真实世界多中心疗效分析

2025-12-040
OAAI
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia

真实世界多中心分析CPX-351在60岁以下继发性急性髓系白血病患者中的疗效

2025-10-260
OA
Prothrombotic profiles in myelofibrosis: Fibrinogen oxidation and the beneficial effects of ruxolitinib

原发性骨髓纤维化中的促血栓形成表型:纤维蛋白原氧化及鲁索利尼布的益处

2025-10-180
OAAI
Revised “iRR6” model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib

修订后的“iRR6”模型在风险分层为1级的骨髓纤维化患者中使用鲁索利替尼治疗

Cancer
IF5.1
2025-08-210
OAAI